Transcript Highlights:

• the birth of her child to also conduct a mental health screening to check for signs of postpartum depression

Bills: SB1423, SB1426, SB1502, SB1377, SB1983, SB1466, SB1645, SB1647, SB1847, SB1565, SB1562, SB1329, SB1383, SB1833, SB1555, SB1344

Keywords: Oklahoma Hospital Advisory Council, hospital licensure, public health, State Department of Health, State Board of Health, hospital regulations, healthcare regulation, hospital standards, hospital construction, hospital operations, stroke care, stroke system, emergency medical services, EMS transport, psychiatric treatment, chemical dependency treatment, substance use disorder, drug storage, pharmacy, quality indicators

Transcript Highlights:

• the birth of her child to also conduct a mental health screening to check for signs of postpartum depression

Bills: SB1423, SB1426, SB1502, SB1377, SB1983, SB1466, SB1645, SB1647, SB1847, SB1565, SB1562, SB1329, SB1383, SB1833, SB1555, SB1344

Keywords: Oklahoma Hospital Advisory Council, hospital licensure, public health, State Department of Health, State Board of Health, hospital regulations, healthcare regulation, hospital standards, hospital construction, hospital operations, stroke care, stroke system, emergency medical services, EMS transport, psychiatric treatment, chemical dependency treatment, substance use disorder, drug storage, pharmacy, quality indicators

Summary: The Health and Human Services committee met and advanced a series of Senate bills, beginning with SB 1423, which repeals the Hospital Advisory Council because of repeated quorum and appointment problems; members discussed whether the council could instead be restructured, but the bill passed 9-1. SB 1426 changed vulnerable adult abuse reporting so only substantiated findings are reported, and SB 1502 repealed the Long-Term Care Advisory Council after it completed its original task; both passed unanimously. The committee also approved SB 1377 to provide duffel bags for children entering foster care and SB 1983 to support resource family partners and improve foster care/adoption outcomes, both by unanimous votes. Members then passed SB 1466, which extends the sunset on the advisory committee on midwifery after adopting an amendment changing the extension date; SB 1645, which sets rules and best practices for OHCA audits of medical providers; SB 1647, which allows up to $1 million from the County Community Safety Investment Fund to support evidence-based pretrial diversion programs through the Indigent Defense System; and SB 1847, which lets certain Advantage Waiver Medicaid recipients with cognitive impairment remain in assisted living and age in place. The committee also approved SB 1565, establishing the framework for Oklahoma to receive federal Transforming Maternal Health Model grant funds, after adding a reporting amendment requiring a final report to state leaders. Additional bills passed included SB 1562, described as an anti-poaching measure for hospice patients that holds hospices responsible for contractor conduct; SB 1329, requiring postpartum mental health screening during Medicaid-covered visits within a year after birth; SB 1383, a technical cleanup to the diabetes self-management education program; SB 1833, directing DHS to apply for a SNAP waiver to restrict certain purchases such as candy and soft drinks; and SB 1555, updating the statutory definition of intellectual disability to align with federal and Social Security standards. The final measure, SB 1344, created an insulin access and affordability program at the State Department of Health to expand low-cost insulin access and competition; it drew discussion about funding, pricing, and the nonprofit partner involved, and passed 9-2. The committee adjourned after the chair noted more double-assigned bills would be heard the following week.

Transcript Highlights:

• disorder, or depression.
• or not depressed.
• or not depressed...
• or not depressed.
• or not depressed.

Summary: The Committee on Science and Technology met to hear a presentation from Ananya Lakaraju, a Hamilton High School junior, on her research into the biology of major depressive disorder. She described a project using saliva metabolomics and machine learning to identify potential biomarkers of depression from a UCSD dataset of 261 patient samples, explaining that the goal was to move beyond subjective screening toward more objective, biology-based diagnosis. She also discussed using multiple statistical methods and an ensemble AI model, along with SHAP and permutation importance, to identify top metabolites and related pathways, and said her work suggested some novel biomarkers and possible links to depression-related pathways. Lakaraju further explained a drug-discovery component of the project, in which she used pathway analysis and molecular docking software to identify a potential target protein and test candidate compounds, saying flupinazine showed the best binding energy in her simulations. She noted that the model achieved about 90% accuracy and a 97% AUC, and said she also built an app to collect mood and activity information to complement the biological data. Members asked questions about the metabolites, whether the findings were novel, how the saliva data were obtained, and how the app and future at-home testing might work. She said the biomarkers were computationally identified, the saliva data came from an online UCSD dataset rather than direct collection, and the app was intended to support more holistic diagnosis rather than replace clinicians. Committee members praised the presentation as impressive and timely, especially in light of the growing role of AI in medicine and the need for AI regulation. Lakaraju also spoke about her interest in coding and biology, her experience in robotics, and receiving the Governor’s Future Innovator of the Year Award. No formal votes or legislative actions were taken, and the meeting adjourned after the presentation and discussion.

Transcript Highlights:

• or not depressed.
• or not depressed... ...ultimately result in a single output of depressed or not depressed.
• Depression severity.
• or not depressed.
• or not depressed.

Keywords: 1182, all

Transcript Highlights:

• People with depression have a 40% higher risk of developing cardiac disease, hypertension, stroke, diabetes
• Kennedy, has been supportive of more than just psilocybin in use as a treatment for depression and other
• Psilocybin you can read dramatic dramatically reduce addiction and depression.
• For years I struggled with severe depression and a very unhealthy relationship with alcohol.
• I no longer live under the weight of severe depression.

Keywords: 1183, house

Transcript Highlights:

• </c> acute um you know acute depression acute um you know acute depression actually<01:24:05.040><c>
• depression who is actually acute depression who is determining<01:24:06.679><c> that</c><01:24:07.199
• </c><01:24:14.040><c> by</c> know I'm probably acute depression by know I'm probably acute depression
• </c> to a concern and we add aute depression to a concern and we add aute depression on<01:34:18.520>
• </c> streets because you're really depressed streets because you're really depressed yes<01:35:12.760

Keywords: 1191, senate, all

Transcript Highlights:

• diagnosed with major depressive disorder will eventually meet the criteria for treatment-resistant depression
• Currently, major depression and treatment-resistant depression, about 60% of the time, is refractory.
• Currently, major depression and treatment resistant depression, about 60% of the time is refractory.
• managed, not depression is not being managed.
• I specialize in treatment-resistant depression.

Summary: The Senate Health and Long-Term Care Committee met on January 27 and heard extensive public testimony on several bills before moving into executive session. Senate Bill 5921 would create a Department of Health medical psilocybin program for adults with qualifying conditions, with licensed producers and clinician participation requirements, training, background checks, and program standards. Supporters, including the sponsor and many clinicians, veterans, first responders, and patients, described psilocybin as promising for treatment-resistant depression, PTSD, trauma, and end-of-life anxiety, while opponents and some medical groups raised concerns about missing safeguards, contraindications, monitoring, cost, and the bill’s narrow medical model. Testimony was split sharply, with many also urging broader decriminalization or community-use protections. The committee later heard Senate Bill 6115, which would have the Department of Health contract for age-appropriate cancer education for grades 6-12; supporters from Cancer Pathways, educators, and families said it would improve prevention and risk awareness, while the bill drew substantial opposition in sign-in counts, and the hearing was ultimately closed without action that day. The committee also heard Senate Bill 5185, a pilot pathway for international medical graduates to obtain full unrestricted primary care licensure after supervised clinical practice, completion of exam and competency requirements, and annual reporting. The sponsor, Washington Medical Association, the Medical Commission, and IMG advocates said the proposal would expand access to primary care while maintaining patient safety, and the bill received supportive testimony. In executive session, the committee adopted proposed substitutes and advanced Senate Bill 5916 on non-opioid pain drugs, Senate Bill 5985 on endometriosis, Senate Bill 6019 on home care rate statutes, Senate Bill 6161 on dementia information, and Senate Bill 6183 on HIV antiviral drug coverage. For Senate Bill 5981 on the 340B drug pricing program, the committee adopted an amendment adding reporting and transparency requirements before moving the bill forward. The committee then adjourned, and the remaining hearing items were rescheduled for a later date.

Transcript Highlights:

• Left untreated, postpartum depression and anxiety can lead to long-term consequences for both mother
• My PMAD symptoms presented differently than traditional depression.
• After having Sadie, I started experiencing some postpartum anxiety and depression symptoms.
• I have no history of anxiety, depression, or mental illness, so it came as a surprise to me.
• Like many others, my symptoms didn't look like classic postpartum depression.

Keywords: 995, all

Summary: The Joint Committee on Mental Health, Substance Use, and Recovery held a public hearing on 17 bills focused on behavioral health workforce shortages, studies, and commissions. Chairs Mindy Domb and Senator John Velis opened by emphasizing the severity of the Commonwealth’s mental and behavioral health workforce crisis, the resulting gaps in access to care, and the legislature’s ongoing use of loan repayment programs, studies, and commissions to address these issues. They outlined hearing procedures and noted that testimony would be limited to three minutes, with written testimony also accepted. A major portion of the hearing focused on bills to expand the primary care workforce, including H. 2205/S. 1385, which would broaden eligibility for the Mass RePay loan repayment program. Testimony from the Massachusetts Medical Society, Senator Jo Comerford, and Dr. Kate Atkinson described severe primary care shortages, long wait times, physician burnout, high debt burdens, and the need to recruit and retain physicians in more practice settings and regions. Committee members asked about the likely impact of loan repayment, the role of nurse practitioners and physician assistants, and how to prioritize limited funding. Witnesses argued that primary care investment improves access and outcomes and that the bill would help sustain community-based practices. Another large block of testimony supported H. 2208/S. 1411, the proposed perinatal behavioral health care workforce trust fund, often referred to as the Moms Matter Act. March of Dimes, perinatal mental health advocates, doulas, clinicians, parents, and organizations such as the Boston Public Health Commission and Empty Arms Bereavement Support testified that postpartum depression, anxiety, substance use, and grief are widespread, often untreated, and worsened by long waitlists and a shortage of trained, culturally competent providers. Speakers repeatedly stressed that screening alone is not enough without a workforce to provide timely treatment, and several shared personal stories of postpartum illness, loss, and difficulty accessing care. The bill was also framed as a needed complement to the Commonwealth’s recent maternal health law, which increased screening and therefore increased demand for treatment. The committee also heard support for the Bridge Act, H. 2207/S. 1388, which would create mental health capacity grants for organizations serving communities at high risk of hate crimes or hate incidents. Testimony from the Jewish Community Relations Council and the bill’s sponsor described the mental health harms of hate, including anxiety, trauma, isolation, and loss of trust, and argued that community organizations need resources to build resilience and provide support. In addition, the committee heard from the Massachusetts Mental Health Counselors Association on H. 2218/S. 1380, which would update job classifications to explicitly include licensed mental health counselors and licensed supervised mental health counselors in state behavioral health roles. Witnesses said the change would modernize hiring, expand access, and better reflect current licensure and scope of practice. No votes were taken during the hearing, and the session ended with a motion to adjourn after all testimony was completed.

Transcript Highlights:

• diagnosed with major depressive disorder will eventually meet the criteria for treatment-resistant depression
• Currently, major depression and treatment-resistant depression are refractory about 60% of the time.
• managed, not depression is not being managed.
• I specialize in treatment-resistant depression.
• There's more studies on depression than there are on PTSD.

Bills: SB5921, SB5185, SB6182, SB6115, SB6258, SB5916, SB5981, SB5985, SB6019, SB6161, SB6183

Keywords: psilocybin, mental health, therapy, decriminalization, legalization, international medical graduates, preceptorship, hardship pathways, medical practice, licensure, abortion, reproductive health, pregnancy termination, clinic access, abortion access fund, abortion savings account, health carrier assessment, insurance assessment, health insurer tax, Department of Health

Transcript Highlights:

• . depression. depression.
• And so, this is for treatment-resistant depression.
• Senator Fillingane. >> And so, this is for treatment-resistant depression.
• Um, treatment-resistant depression, substance use disorder, and other mental health indications.
• Um, treatment-resistant depression, substance use disorder, and other mental health indications.

Keywords: Drug Policy - Room 409, 26 February, 2026; 2:30 P.M., 925, all

Transcript Highlights:

• That animals demonstrate abstinence, withdrawal, respiratory depression at higher doses.
• Higher doses mean more risk of respiratory depression.
• does not work on opioid receptors and cause respiratory depression like 7-OH.
• And it also helped me with depression.
• In my life, it's been meaningfully helpful for pain, anxiety, and depression.

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. Members referenced AB 1088, which would be considered later, and said the hearing was intended to clarify the science, medical perspective, and whether stronger safeguards are needed. The first panel featured a toxicology expert, state and local public health officials, an emergency/addiction physician, a medical examiner, and county health representatives. Witnesses from CDPH and Los Angeles County described rising deaths and enforcement actions, including statewide advisories, retailer letters, and product removals from manufacturers, wholesalers, and retailers. Medical testimony emphasized that 7-OH acts much more like an opioid than traditional kratom leaf, can cause dependence, withdrawal, and respiratory depression, and may require naloxone, buprenorphine, or methadone in overdose or withdrawal cases. Local officials said enforcement is difficult because packaging is inconsistent, testing capacity is limited, and counties lack resources and statewide infrastructure; they generally favored a centralized state framework if regulation is pursued. Committee members asked about testing, age restrictions, scheduling, and whether a distinction between kratom and 7-OH could be enforced. Witnesses said forensic labs can potentially test for 7-OH but validated assays are not routine, emergency departments cannot readily distinguish exposures, and local health departments do not have the lab capacity to verify product labels. Several officials warned that a ban or abrupt scheduling could push products into the black market and discourage research, while others argued that current prohibition and enforcement are the most protective approach because legalization or age-limited regulation could create confusion about legality and safety. The second panel included kratom and 7-OH advocates and industry representatives, who argued that natural kratom leaf and concentrated or synthetic 7-OH are different products and should be regulated differently. They supported age-gating, labeling, testing, and packaging rules for kratom leaf while opposing a ban on the botanical. They said 7-OH is used by many adults for pain relief or harm reduction, and that prohibition would drive consumers to illicit markets and worsen harm. Committee members pressed them on whether 7-OH is more potent than kratom, the availability of testing, and whether any safe dose is known. The hearing ended without a vote or formal action, with the chair noting the issue will continue to be considered in future legislation.

Transcript Highlights:

• Unresponsive, you know, respiratory depression and so on.
• Higher doses mean more risk of respiratory depression.
• does not work on opioid receptors and cause respiratory depression like 7-OH.
• And it also helped me with depression.
• In my life, it's been meaningfully helpful for pain, anxiety, and depression.

Keywords: 987, senate, all

Transcript Highlights:

• It was a small carrier that did not cover postpartum depression screening.
• Uh, Senator Boyd, I think depression.
• Um and we when we did a depression.
• And um postpartum depression screening.
• The bill provides for depression screening, and it's a very straightforward bill.

Keywords: Medicaid - Room 216, 29 January, 2026; 2:00 PM, 925, all

Transcript Highlights:

• Like many other service members, I struggled with PTSD, anxiety, and depression.
• Like many other service members, I struggled with PTSD, anxiety, and depression.
• Suicide remains one of the most horrific complications of postpartum depression here in Hawaii.
• </c> complications of postpartum depression complications of postpartum depression um<00:54:13.319><c
• </c> with treatment resistant depression with treatment resistant depression anxiety<00:54:55.680><c>

Keywords: 912, senate, all

Summary: The Health and Human Services Committee heard testimony on several measures related to child welfare, health care access, overdose response, disability services, and waste management. For SB 710 on child welfare, the Department of Human Services, the Office of Wellness and Resilience, the Attorney General’s office, and multiple advocacy groups testified in support, with the Governor’s office noting support but deferring to the Attorney General on implementation because of separation-of-powers concerns. For SB 952 on child welfare services, DHS, the Governor’s office, and child- and trauma-informed care advocates supported the bill, saying it would help families access services, provide basic material support, and reduce strain on the child welfare system. SB 954 on a home health services rate study also drew support, including from DHS, the Hawaii Healthcare Association, and a public testifier who said the study would help ensure funds reach low-income, disabled, and kupuna recipients. SB 957 on overdose prevention received support from the Department of Health and the Attorney General, who said overdose prevention centers are evidence-based but raised federal-law concerns and recommended amendments; the Hawaii Health and Harm Reduction Center and others also testified in support. The committee then moved to the 1:00 regular calendar and heard SB 850 on disability health disparity, which was supported by the Executive Office on Aging, the Hawaii State Council on Developmental Disabilities, the Hawaii Disability Rights Center, self-advocates, and others. Testimony emphasized that a disparity study could improve workforce development, training, and services for people with disabilities. SB 838 on continuous glucose monitoring drew support from health agencies and advocates, with testimony stressing that monitors can be critical for some diabetes patients. SB 829 on health care was supported by the Department of Health and health care stakeholders, who said it would help rotating physicians serve neighbor islands without local hospital privileges and align with CMS rules. SB 446 on waste management drew mixed testimony: the Department of Health and several public entities provided comments, the County of Maui opposed, and environmental advocates urged stronger aquifer protections and limits on ash reuse. During decision making, the committee adopted recommendations to pass SB 298, SB 322, SB 299, SB 450, SB 451, SB 949, SB 710, SB 957, SB 69, and SD 952 with various amendments, including technical changes, blank appropriations, and defective dates. SB 323, SB 324, SB 712, SB 950, SB 954, and SB 959 were deferred, largely because companion House measures were moving or similar Senate measures had already passed. The chair also announced recesses to find quorum and noted that some bills from the earlier Monday calendar were being deferred to avoid duplication.

Transcript Highlights:

• </c> will use the term PTSD and depression. will use the term PTSD and depression.
• And all you need to really depression.
• </c> So, um, addiction, PTSD, and depression So, um, addiction, PTSD, and depression all<00:32:13.760
• ><c> as</c><00:32:30.559><c> damaging</c> don't think of depression as damaging don't think of depression
• </c> category, not in the PTSD or depression category, not in the PTSD or depression category. category

Keywords: 958, all

Summary: The committee first reviewed preferred administrative regulations and, hearing no concerns, considered them reviewed. It then took up House Bill 388, described as a Casper cleanup bill. The sponsor said it would exempt charitable health care providers from e-prescribing requirements, allow Casper data sharing with certain federal entities, update references to hydrocodone’s schedule status, clean up drafting errors, and clarify practitioner registration with Casper. The bill passed 9-0 and was then approved for consent. Next, House Bill 134 was presented as a follow-up to a prior study on shortages of sexual assault nurse examiners and SANE-ready hospitals. The sponsor and a representative from the Kentucky Association of Sexual Assault Programs said the bill would create a statewide SANE coordinator. The committee adopted a substitute, then passed the bill unanimously and sent it to consent. Senate Bill 147 was then heard as an administrative update to vital records, modernizing certified-copy requests, adjusting fees, and requiring the Cabinet for Health and Family Services to send the annual death report to the State Board of Elections by July 1 each year. It passed unanimously and was also moved to consent. House Bill 280, a Kentucky Board of Nursing cleanup bill, would let the board investigate out-of-state nurses applying for Kentucky licenses, clarify licensing language, and update school rescue medication provisions, including inhalers, nebulizers, glucagon, Solu-Cortef, and nasal epinephrine. A committee substitute narrowed the bill to glucagon updates, and one senator asked whether the bill also covered child care centers; the sponsor said it addressed school medications only but was open to further discussion. The bill passed 10-0 and was reported favorably. Finally, Senate Bill 77 drew extended testimony. The sponsor and supporters argued that ibogaine research and treatment could help address addiction, PTSD, and depression, citing studies, personal recovery stories, and a proposed public-private partnership funded through opioid settlement money. The committee substitute removed the bill’s appropriation request and emergency clause, and members asked questions about whether PTSD is an addiction, whether smoking was included, whether the bill was authorizing research rather than funding, and how the treatment works. The sponsor said the substitute was only creating a structure for research, not appropriating money, and supporters described ibogaine as a one-time, medically supervised treatment. The transcript cuts off before a final vote on Senate Bill 77 is shown.

Transcript Highlights:

• Um, mandatory depression screenings require that each inmate who is pregnant or has given birth in the
• preceding year be screened for depression at specific intervals.
• HB 1826 will help address this by requiring regular depression screenings for incarcerated women during
• Maternal depression can disrupt infant development and bonding.
• Approximately 1/3 of the women's jail prison population suffers from some form of depression.

Transcript Highlights:

• Nearly half of patients with depression actually never seek care.
• Nearly half of patients with depression actually never seek care.
• ,</c><00:04:44.080><c> anxiety</c> can be as simple as depression, anxiety can be as simple as depression
• </c> Nearly half of patients with depression Nearly half of patients with depression actually<00:04:52.720
• So self-dagnosed anxiety or depression.

Keywords: 00:00 - Call to Order/Roll Call 02:05 - Discussion of 26RS HB 178 14:05 - Roll Call Vote on 26RS HB 178 15:05 - Discussion of 26RS HB 280 20:00 - Roll Call Vote on 26RS HB 280 22:00 - Discussion of 26RS HJR 24 24:30 - Roll Call Vote on 26RS HJR 24 26:00 - Adjournment, 958, all

Transcript Highlights:

• Higher doses mean more risk of respiratory depression.
• does not work on opioid receptors and cause respiratory depression like 7-OH.
• And it also helped me with depression.
• And it also helped me with depression.
• In my life, it's been meaningfully helpful for pain, anxiety, and depression.

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful for consumption, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. The hearing was framed as part of ongoing legislative work, including a future review of AB 1088, and members emphasized the need to weigh potential benefits against risks and consider whether stronger safeguards are needed. Expert testimony from a toxicology professor and several public health and medical officials described kratom as a plant with multiple alkaloids, with 7-OH identified as the more potent opioid-like compound associated with tolerance, dependence, withdrawal, and respiratory depression. CDPH reported 362 kratom-related overdose deaths in California from 2019 to 2023 and 15 deaths involving 7-OH, while Los Angeles County officials described unexplained deaths in young adults that led them to expand toxicology testing and identify 7-OH as a common factor. County and state public health representatives said they have issued advisories, contacted retailers, removed products from shelves, and taken enforcement actions, but they stressed that local enforcement is patchy, under-resourced, and limited by unclear jurisdiction and lack of testing capacity. Medical witnesses said patients are presenting with 7-OH dependence and withdrawal in ways similar to fentanyl-related cases, sometimes requiring buprenorphine, methadone, or repeated naloxone. They argued that unregulated retail sales and misleading marketing make the products especially risky, and that a statewide framework would be more effective than a patchwork of local ordinances. Some officials said the safest current policy is to keep kratom and 7-OH unlawful for consumption, while others said any new regulation would need resources, packaging rules, and clearer authority for enforcement. Industry and consumer advocates urged the committee to distinguish natural kratom leaf from concentrated or synthetic 7-OH products. They argued that kratom leaf has long-standing use, that 7-OH should be targeted rather than the whole plant, and that regulation should focus on age limits, labeling, testing, serving-size caps, and restrictions on adulterated products rather than prohibition. Several speakers warned that bans could push demand to the black market and reduce access for people using the products for pain relief or harm reduction, while critics of the industry said the products are being marketed deceptively and that more comprehensive regulation is needed.

Transcript Highlights:

• According to the Anxiety and Depression Society of America, one in 10 experience depression.
• According to the Anxiety and Depression Society of America, one in 10 experience depression.
• According to the Anxiety and Depression Society of America, one in 10 experience depression.
• Depression is real.
• Depression is real.

Keywords: U.S. House of Representatives Floor Proceedings on Monday, June 9, 2025, 1012, house, all

Transcript Highlights:

• Unfortunately, here in Hawaii, we have witnessed a sharp increase in depression and anxiety amongst our
• An estimated 10,000 young folks ages 12 to 17 suffer from depression, yet nearly 69% do not receive any
• :02:02.439><c> sharp</c><00:02:02.799><c> increase</c><00:02:03.200><c> in</c><00:02:03.399><c> depression
• </c> witnessed a sharp increase in depression witnessed a sharp increase in depression and<00:02:04.280
• Young Folks ages 12 to 17 suffer 10,000 Young Folks ages 12 to 17 suffer from<00:02:12.200><c> depression

Keywords: 912, senate, all